A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.
Listed as NCT05318573, this PHASE2 trial focuses on Advanced Non Small Cell Lung Cancer and Advanced Urothelial Carcinoma and remains ongoing. Sponsored by Fujifilm Pharmaceuticals U.S.A., Inc., it has been updated 18 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
18 versions recorded-
Oct 2025 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 13 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Jun 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Jun 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .